"Spinal muscular atrophy treatment market to exhibit dynamic growth during the forecast period"
The global spinal muscular atrophy treatment market is growing proficiently, expected to grow at a CAGR of 14.5%. Globally, the increasing incidence of SMA along with improved treatment management by innovative gene therapy and drugs will drive the growth of the market. Increasing awareness, FDA approval for new drugs, partnerships for enhanced R&D and private funding will boost the overall demand of SMA treatment on a global scale.
"Type I SMA treatment to witness a significant CAGR"
Growing hospital admissions for type I SMA and its therapeutic treatment generated maximum revenue share in 2021. Increasing incidences of SMA in infants and advancement in gene therapy along with strong pipeline drugs internationally will drive the market growth. New drug development for type II and III will show promising growth in the near future, enhanced joint development programs for innovative therapies will drive the demand in the near future such as Risdiplam (RG7916), Reldesemtiv (CK-2127107), Branaplam (LMI070) and others.
"Gene therapy treatment to witness a significant CAGR in the near future"
Drugs accounted for the maximum revenue share in 2021. In 2020, drugs emerged as the principal treatment application for spinal muscular atrophy (SMA) since Spinraza (developed by Biogen & Ionis Pharmaceuticals) is the only drug approved till date. Additionally, in May 2021, the U.S. FDA approved Zolgensma® (onasemnogene abeparvovec-xioi) by AveXis (Novartis AG), the first gene therapy for infants (less than 2 years of age) suffering with spinal muscular atrophy. Advancement in gene therapy, FDA approval for new drugs, and strong pipeline products offer a huge advantage in the global SMA treatment market. PTC Therapeutics and F. Hoffmann-La Roche AG proceeded with official plans to file for approval in the U.S. market and Europe by the end of 2021, it would set possible approval for the SMA treatment in the first half of 2020.
"Increased research and development with strong product pipelines in the developed regions"
Major players in the spinal muscular atrophy treatment market are Biogen Idec., Pfizer Inc., Boehringer Ingelheim, Isis Pharmaceuticals, F. Hoffmann-La Roche, Regeneron Pharmaceuticals, AveXis Inc., Novartis AG and others. Merger and acquisitions, partnerships and improved R&D on spinal muscular atrophy targeted treatments will further drive the overall market growth in the near future. Strong pipeline drugs will enhance the overall treatment management for SMA, such as Zolgensma (Novartis), Branaplam (Novartis), Amifampridine Phosphate (Catalyst Pharmaceuticals), Risdiplam (Hoffmann-La Roche) and others.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Spinal Muscular Atrophy Treatment market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Region Segment (2020–2030; US$ Million)
Global Impact of Covid-19 Segment (2020-2021; US$ Million )
Key questions answered in this report